Slide 1: Responding To Australia's Mental Health Crisis
ASX : EMD For personal use only Responding To Australia’s Mental Health Crisis Advanced therapies. Compassionate care. 15 October 2025 Sharewise Webinar
Slide 2: Disclaimer
Disclaimer This presentation has been prepared by Emyria Limited ACN 625 085 734 (Company or Emyria). This presentation is not a financial product or investment advice or recommendation, offer or invitation by any person or to any person to sell or purchase securities in Emyria in any jurisdiction.
Slide 3: Emyria At A Glance
Emyria At A Glance For personal use only Private Health insurance TGA rescheduled two funding Emyria’s evidenced Durable and sustained promising mental health based PTSD and Treatment patient outcomes six treatments July 2023 Resistant Depression months post treatment programs Emyria’s programs in t
Slide 4: Corporate Overview
Corporate Overview ASX: EMD Trading Information Share Price For personal use only Last Traded Share Price A$0.065 12-Month low / high A$0.021 / 0.072 Shares Outstanding 665,105,663 Unlisted Options (including loyalty options) 318,825,466 Market Capitalisation 1 ~A$44.0m Last Cash Position 2 ~A$4.685
Slide 5: Mental Health Is Australia's #1, Rising, Chronic Health Problem
Mental Health Is Australia’s #1, Rising, Chronic Health Problem Inaki Ereno For personal use only Figure 2 : Types of serious illness by age and sex, 2009 to 2021 Bupa CEO 18% 16% Depression / Anxiety 14% 12% 10% 8% 6% Mental health is the new pandemic Cancer but the provision of mental health … 4%
Slide 6: Major Funders Are Spending Hundreds of Millions Each Year on Mental Health
Teams Major Funders Are Spending Hundreds of Millions Each Year on Mental Health For personal use only Private Department of Other Health Insurers Veterans’ Affairs Insurers The Government spends Life insurers … paid out more than $2B $300M/yr on veteran mental health each year. 2 $2.2B in 2024 spen
Slide 7: Australia's Unique Opportunity
Australia’s Unique Opportunity An Access Pathway For Psychedelics to Treat our Most Serious and Urgent Mental Health Conditions For personal use only MDMA-assisted therapy Australia for PTSD is the FIRST jurisdiction in the Psilocybin-assisted therapy world to reschedule two promising treatments for
Slide 8: Total Addressable Market | PTSD
Total Addressable Market | PTSD Adults with difficult to treat PTSD in Australia For personal use only Early Target Markets ~29,000 current patients With Hospital Cover (~5% Adults 2) Australian Adults Serviceable Addressable With PTSD Market (SAM) ~34,000 current patients Veterans (~17% of Veterans
Slide 9: Total Addressable Market | Treatment Resistant Depression
Total Addressable Market | Treatment Resistant Depression Adults with difficult to treat depression in Australia For personal use only Early Target Markets ~20,000 current patients with Hospital Cover (~5% Adults 2) Australian Adults With Serviceable Addressable Major Depression Market (SAM) ~18,300
Slide 10: Emyria Has Overcome Major Barriers To Psychedelic Delivery
Emyria Has Overcome Major Barriers To Psychedelic Delivery And Is Now Building An Operational Moat For personal use only Skilled Secure Therapists Drug Supply Third Authorised Party Prescribers Funding Proven Fit-for- Purpose Clinical Model Facilities 10 Advanced therapies. Compassionate care.
Slide 11: Emyria's P-AT Treatment Model
Emyria’s P-AT Treatment Model Medication, ~90 hours of Supervised Intensive Psychotherapy, Follow-Up For personal use only ACTIVE TREATMENT PROTOCOL DOSING DOSING DOSING CYCLE 1 CYCLE 2 CYCLE 3 FOLLOW-UP PERIOD SCREENING AND (12 months from last PREPARATION Dosing Treatment Cycle) Dosing Dosing Day
Slide 12: Emyria's PTSD Program Is Delivering Results
Emyria’s PTSD Program Is Delivering Results Case Study Kate | From “Permanent Disability” To Back at Work For personal use only MDMA-AT 5 years commenced PCL-5 < 30 70 Kate’s story: First responder 60 • PTSD due to cumulative workplace traumas 50 • Myriad of therapies: EMDR, in-vivo, ACT, CBT, mindf
Slide 13: Emyria's PTSD Program | Return-To-Work Progress
Emyria’s PTSD Program | Return-To-Work Progress To Date, 10 Out of 10 Patients With Work-related PTSD Have Returned To Work 6 M Post-treatment For personal use only 6-8 weeks 6-months 0% working 25% 100% planning return to work back to gainful Start of treatment employment End of treatment 6m post t
Slide 14: Emyria's PTSD Program Is Delivering Results
Emyria’s PTSD Program Is Delivering Results Durable symptom and quality of life improvement, beyond 6 months from a single treatment Baseline For personal use only Our Empax Model matches Phase 3 trial outcomes out to 6 months. >60% of patients no longer meet criteria for % of patients with PTSD dia
Slide 15: Medibank Agreement
Medibank Agreement Emyria is the only provider Medibank has currently partnered with For personal use only Multi-year agreement1 Fully fund eligible, screened patients1 Uncapped patient numbers1 Commenced treatment under the agreement for PTSD patients in August 2025 (Perth)2 Agreement expanded to i
Slide 16: Other Funders
Other Funders DVA > Workers Compensation > Others For personal use only Workers Compensation and other funders Case by case funding approval occuring First responders more likely to experience PTSD2 DVA to fund Psychedelic Assisted Therapies for its members1 1.https://ww w.blackdoginstitute.org.au /
Slide 17: Accelerating a National Roll-out
To Meet Rising Patient Demand, Emyria Is Accelerating a National Roll-out For personal use only (1) Community Clinic 1 3 1 2 (2) Perth Clinic 2 Current Near term potential Sites sites SOURCES: 1. See ASX release 14 th April 2025 (3) Avive Clinic (QLD) 3 2. See ASX release 29 Ju ly 2025 17 Advanced t
Slide 18: Emyria's Growth Strategy
Emyria’s Growth Strategy Secure Site Partners > Grow Capacity > Optimise Utilisation Currently active or in Additional East Coast For personal use only Perth Clinic Perth Clinic Perth Clinic preparation sites under consideration Total Funded Dosing Days Available / week 2 beds x 2 days 2 beds x 5 da
Slide 19: Milestones
Emyria (ASX:EMD) | Milestones Target activities For personal use only Expanded funded programs Grow capacity nationally to include Depression Treatment via new site partners Expand funders for our Optimise utilisation to programs grow revenues 19 20 Advanced therapies. Compassionate care.
Slide 20: Why Invest Now?
Why Invest Now? Unique Timing. Proven Model. Overcome High Barriers To Entry. Programs Funded. For personal use only is tackling some of the most serious health challenges of our generation First Mover Significant Moat Immediate Growth Advantage (High Barriers Overcome) and Revenue Potential 20 Adva
Slide 21: Emyria Board
Emyria Board Significant Clinical Services & Global Innovation Expertise For personal use only Greg Hutchinson Dr Michael Winlo Dr Karen Smith Dr Mohit Kaushal Prof Sir John Tooke Executive Chairman Executive Director Non-Executive Director Non-Executive Director Non-Executive Director Health Servic
Slide 22: Contact Information
Contact Information For personal use only Greg Hutchinson ghutchinson@emyria.com Mary-Ann Rennie mrennie@emyria.com Investor / Visit Our Media Inquiries Investor Hub investors@emyria.com